Brief: Cantargia Expands Can10 Phase 1 Clinical Program Building On Positive Results
29/11/2024 14:24
Nov 29 (Reuters) - Cantargia AB CANTA.ST :
* CANTARGIA EXPANDS THE CAN10 PHASE 1 CLINICAL PROGRAM
BUILDING ON
POSITIVE RESULTS
Source text: ID:nMFNbfcW8v
Further company coverage: CANTA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML